MMED Stock Forecast & Price Target

Minimed Group is appealing because it has emerged from Medtronic under a cleaner, more focused stand-alone structure while retaining a rare end-to-end diabetes platform spanning pumps, CGMs, smart pens, consumables, and pharmacy fulfillment. The company is regaining share and prescriber confidence after years of setbacks, with 1Q FY27 revenue of $843M, low-double-digit organic growth excluding an extra week, and CGM attachment rising to about 69%, while management lifted FY27 organic growth guidance to roughly 10.5% and reiterated ~16% EBITDA margin. Its pipeline of Flex, Fit, Vivera, and the next-gen sensor, plus a leadership team that has already driven remediation and product refreshes, supports roughly 10% organic revenue CAGR through FY29E and expanding profitability.

Minimed Group is facing a difficult competitive and operational setup, with downside risk from slower new-patient starts, renewal churn, and potential delays to the planned summer 2027 launch of the FIT patch pump. Its dependence on Abbott as the exclusive third-party CGM supplier, uncertain pharmacy-channel economics, and rising pharmacy price pressure could all limit adoption and profitability, while a larger-than-expected GLP-1 impact could slow Type 2 insulin-pump growth. Margin expansion also appears constrained by remaining transition service agreements, standalone buildout costs after the spin from MDT, and the Blackstone royalty structure that could add about $162M in one-time non-cash charges at FDA approval.